Therapix Biosciences Ltd. (TRPX) News
Filter TRPX News Items
TRPX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest TRPX News From Around the Web
Below are the latest news stories about Therapix Biosciences Ltd that investors may wish to consider to help them evaluate TRPX as an investment opportunity.
Nasdaq to delist Therapix Biosciences; shares down 43%Nasdaq has informed Therapix Biosciences (TRPX) that it will delist its American Depositary Shares (ADSs) effective tomorrow, July 2, at the open.Yesterday, an Israeli court granted a temporary injunction against the company barring it from making any changes to its share capital or adopting any resolution outside of the normal... |
Therapix Biosciences Receives Notice of Delisting and Injunction from Israeli CourtTherapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company" or "Therapix"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today receipt of Notice of Delisting and Injunction from Israeli Court. |
Therapix Biosciences raises $2.6M in private placementTherapix Biosciences (TRPX) entered into definitive agreements for the issuance of an aggregate of 5.2M ADSs at a purchase price of $0.50/ADS, and warrants to purchase up to 2.6M ADSs in a private placement.The private placement is expected to result in gross proceeds to Therapix of $2.6M.Net proceeds will be used... |
Therapix Biosciences raises $2.6M in private placement (NASDAQ:TRPX)Therapix Biosciences (NASDAQ:TRPX) entered into definitive agreements for the issuance of an aggregate of 5.2M ADSs at a purchase price of $0.50/ADS, and w |
Therapix Biosciences Raises $2.6 Million in Private PlacementTEL-AVIV, Israel, June 29, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced that it has entered into definitive… |
Pure Capital Demands Replacement of Therapix Biosciences Ltd.'s Board of DirectorsPure Capital today announces that it has sent a letter to the chief executive officer, chairman of the board and the directors of Therapix Biosciences Ltd. (TRPX), calling for an immediate general meeting of the shareholders of Therapix Biosciences and the dismissal of all members of the board. In the letter, Pure Capital detailed previous actions which it believes have been harmful to shareholders. |
Therapix Biosciences Closes A Joint Venture Transaction For its Sleep IndicationTEL AVIV, Israel, May 19, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company" or "Therapix"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today that it has closed a joint venture… |
Therapix Biosciences Appoints Prof. Ari Shamiss (M.D., M.P.A.) to the Company's Board of DirectorsTEL AVIV, Israel, May 7, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announces today the appointment of Prof. Ari Shamiss (M.D., M.P.A.) to the… |
Therapix Biosciences Appoints Prof. Ari Shamiss (M.D., M.P.A.) to the Company's Board of DirectorsTherapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announces today the appointment of Prof. Ari Shamiss (M.D., M.P.A.) to the Company's Board of Directors. |
Therapix Biosciences Announces Appointment of New CEOTEL AVIV, Israel, April 22, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today the appointment of Mr. Gilad Bar-Lev as CEO of the… |